Stem cell therapy for immune-related disorders
Part of Immune system & allergy clinical trials.
This trial is testing an experimental treatment using special cells called clonal fetal mesenchymal stem cells (cfMSCs) to help control overactive immune responses. The goal is to reduce symptoms of immune disorders like graft-versus-host disease (GVHD) when other treatments have not worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or a loved one have an immune-related disorder, including graft-versus-host disease (GVHD) after a transplant.
- There is no other standard treatment that can reduce your symptoms.
- You do not currently have an active infection.
- You have no history of cancer.
- You are expected to live for at least two weeks.
- You are not pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a special stem cell treatment can help people with moderate to severe COPD when regular medicines are not working well. The treatment may reduce breathing problems and improve quality of life.
This study tests whether giving special stem cells (called mesenchymal stem cells) can help improve poor graft function after a stem cell transplant. It aims to boost your blood cell counts so you recover better.
This study tests whether an experimental cell therapy called iMSC can help prevent graft-versus-host disease (a common complication after a stem cell transplant). It is given soon after your transplant, within 5 days of enrolling, and aims to reduce the chance of this serious condition.
This trial tests a new type of stem cell therapy (iMSC) for people with steroid-resistant acute graft-versus-host disease (aGVHD), a serious complication after a stem cell transplant. The goal is to see if it's safe and might help control the disease.
This trial provides a special type of stem cell transplant for people under 22 years old who don't have a fully matched sibling donor. It uses a method to remove certain cells from the donor's stem cells to reduce the risk of graft-versus-host disease, where the donor cells attack the patient's body.
This trial tests a stem cell transplant to treat common variable immunodeficiency (CVID) and other immune problems. It aims to replace a faulty immune system with a healthy one from a donor.
Hear when a new Immune Related Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.